OTCPK:CMXC

Stock Analysis Report

Executive Summary

Cell MedX Corp., a development stage company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions.

Rewards

Earnings have grown 1.3% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($20K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Cell MedX's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CMXC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

23.4%

CMXC

-0.06%

US Medical Equipment

0.6%

US Market


1 Year Return

123.1%

CMXC

25.1%

US Medical Equipment

20.8%

US Market

Return vs Industry: CMXC exceeded the US Medical Equipment industry which returned 25.1% over the past year.

Return vs Market: CMXC exceeded the US Market which returned 20.8% over the past year.


Shareholder returns

CMXCIndustryMarket
7 Day23.4%-0.06%0.6%
30 Day-39.6%3.7%2.5%
90 Day-75.8%4.2%4.9%
1 Year123.1%123.1%26.2%25.1%23.5%20.8%
3 Year31.8%31.8%91.7%86.1%46.5%37.0%
5 Year-58.0%-58.0%117.6%93.8%64.6%46.5%

Price Volatility Vs. Market

How volatile is Cell MedX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cell MedX undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cell MedX is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cell MedX has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CMXC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cell MedX regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Cell MedX forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cell MedX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CMXC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cell MedX's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cell MedX performed over the past 5 years?

1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CMXC is currently unprofitable.

Growing Profit Margin: CMXC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CMXC is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare CMXC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMXC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: CMXC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cell MedX's financial position?


Financial Position Analysis

Short Term Liabilities: CMXC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CMXC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CMXC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CMXC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: CMXC has a low level of unsold assets or inventory.

Debt Coverage by Assets: CMXC has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CMXC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CMXC has less than a year of cash runway if free cash flow continues to grow at historical rates of 37.7% each year.


Next Steps

Dividend

What is Cell MedX's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CMXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CMXC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CMXC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMXC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CMXC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cell MedX's salary, the management and board of directors tenure and is there insider trading?

5.1yrs

Average management tenure


CEO

Frank McEnulty (63yo)

1.3yrs

Tenure

US$43,200

Compensation

Mr. Frank E. McEnulty has been the Chief Executive Officer of Cell MedX Corp since September 12, 2018 and served as its Chief Executive Officer and President of Cell MedX Corp. (formerly Plandel Resources  ...


CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD43.20K) is below average for companies of similar size in the US market ($USD526.35K).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.


Management Age and Tenure

5.1yrs

Average Tenure

60yo

Average Age

Experienced Management: CMXC's management team is seasoned and experienced (5.1 years average tenure).


Board Age and Tenure

3.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: CMXC's board of directors are considered experienced (3.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$2,65015 Aug 19
Richard Jeffs
EntityIndividual
Shares8,564
Max PriceUS$0.32
BuyUS$2,40009 Aug 19
Richard Jeffs
EntityIndividual
Shares16,000
Max PriceUS$0.15
BuyUS$2,13202 Aug 19
Richard Jeffs
EntityIndividual
Shares14,700
Max PriceUS$0.14
BuyUS$3226 Jul 19
Richard Jeffs
EntityIndividual
Shares200
Max PriceUS$0.16
BuyUS$1,53019 Jul 19
Richard Jeffs
EntityIndividual
Shares8,500
Max PriceUS$0.18
BuyUS$18728 Jun 19
Richard Jeffs
EntityIndividual
Shares1,100
Max PriceUS$0.17
BuyUS$7,03011 Feb 19
Richard Jeffs
EntityIndividual
Shares50,250
Max PriceUS$0.14

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Management Team

  • Frank McEnulty (63yo)

    CEO & Director

    • Tenure: 1.3yrs
    • Compensation: US$43.20k
  • Bradley Hargreaves (60yo)

    VP of Technology & Operations and Director

    • Tenure: 2.9yrs
    • Compensation: US$49.34k
  • Yana Silina (41yo)

    CFO, Treasurer

    • Tenure: 3.3yrs
    • Compensation: US$12.00k

Board Members

  • Frank McEnulty (63yo)

    CEO & Director

    • Tenure: 1.3yrs
    • Compensation: US$43.20k
  • George Adams (68yo)

    Independent Director

    • Tenure: 1.8yrs
  • Bradley Hargreaves (60yo)

    VP of Technology & Operations and Director

    • Tenure: 2.9yrs
    • Compensation: US$49.34k
  • Yana Silina (41yo)

    CFO, Treasurer

    • Tenure: 3.3yrs
    • Compensation: US$12.00k
  • Yousef Shihab

    Member of Advisory Board

    • Tenure: 4.3yrs
  • Gregory Pek

    Member of Advisory Board

    • Tenure: 3.1yrs

Company Information

Cell MedX Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cell MedX Corp.
  • Ticker: CMXC
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.187m
  • Shares outstanding: 55.82m
  • Website: https://www.cellmedx.com

Number of Employees


Location

  • Cell MedX Corp.
  • 123 West Nye Ln
  • Suite 446
  • Carson City
  • Nevada
  • 89706
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CMXCOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2013
9CXMUN (Boerse Muenchen)YesCommon SharesDEEURMar 2013

Biography

Cell MedX Corp., a development stage company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/14 01:17
End of Day Share Price2019/12/13 00:00
Earnings2019/08/31
Annual Earnings2019/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.